Two studies presented at the 2023 American Academy of Orthopaedic Surgeons Annual Meeting found that patients who had shoulder arthroplasty could return to play golf or racket sports within six months to one year, experiencing significantly decreased pain as well maintained or improved performance.
In the first study to establish patient satisfaction after outpatient total joint arthroplasty in an academic medical center setting, patients indicated they were very likely to undergo the outpatient procedure again and had high patient reported outcomes.
While the overall number of sports-related injuries is decreasing, the severity of those injuries and the number of head and neck injuries are on the rise, according to a study presented at the 2023 American Academy of Orthopaedic Surgeons Annual Meeting.
Head and Neck Injuries, Severity of Sports Injuries Increasing in High School Athletes Read More »
Patients aged 55 and younger were found to have worse pain, function and quality of life following total knee arthroplasty compared to patients 75 years and older, according to a study presented at the 2023 Annual Meeting of the American Academy of Orthopaedic Surgeons that looked at age-related differences in patient outcomes following TKA.
MRM Health provided a business update on its different ongoing therapeutic programs and an outlook for 2023.
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Noema Pharma, has raised an oversubscribed CHF 103 million Series B financing round.
POXEL SA, clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced publication in Journal of Hepatology of positive results for DESTINY-1, a 36-week dose-ranging Phase 2 trial.
While Electronic Health Records improve access to patient information, charting increases the clerical burden on physicians as medical documentation has been identified as a contributing factor to burnout.
BioMarin Pharmaceutical Inc. today announced that it received notice this afternoon from the U.S. Food and Drug Administration (FDA) that the agency has extended review of the company’s Biologics License Application (BLA) for ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for adults with severe hemophilia A.
The U.S. Food and Drug Administration has accepted, for review, the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.
